Dissemine intravasculary coagulation may be the presenting feature for chronic myelomonocytic leukemia: Special case report
Open Access
- 1 July 2019
- journal article
- Published by Peertechz Publications Private Limited in Archives of Hematology Case Reports and Reviews
- Vol. 4 (1), 011-013
- https://doi.org/10.17352/ahcrr.000018
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemiaLeukemia, 2017
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaBlood, 2016
- Thrombosis and cancerNature Reviews Clinical Oncology, 2012
- Thrombophilic state in cancer, Part I: Biology, incidence, and risk factorsJournal of Surgical Oncology, 2011
- Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcomeCancer, 2007
- Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemiaBlood, 2006
- Decitabine improves patient outcomes in myelodysplastic syndromesCancer, 2006
- Cancer and venous thromboembolismThe Lancet Oncology, 2005
- Plasma Lipoprotein Induction and Suppression of the Generation of Cellular Procoagulant Activity in VitroJCI Insight, 1981
- Mononuclear cell tissue factor: cell of origin and requirements for activationBlood, 1979